Last reviewed · How we verify
Acamprosate or Naltrexone
Acamprosate or Naltrexone is a Small molecule drug developed by Central Institute of Mental Health, Mannheim. It is currently FDA-approved.
Acamprosate and Naltrexone, developed by the Central Institute of Mental Health, Mannheim, are marketed drugs with a key composition patent expiring in 2028. The primary strength of these drugs lies in their established market presence and well-documented efficacy in treating alcohol dependence. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Acamprosate or Naltrexone |
|---|---|
| Sponsor | Central Institute of Mental Health, Mannheim |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combining a Smartphone App With Medications to Manage Heavy Drinking (NA)
- Promoting Medications for Alcohol Use Disorder on the General Medicine Service
- Medication Development in Alcoholism: Acamprosate Versus Naltrexone (PHASE2)
- COMBINE (Acamprosate/Naltrexone) (PHASE3)
- Individually Adapted Therapy of Alcoholism (PHASE4)
- Trial for the Treatment of Alcohol Dependence (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acamprosate or Naltrexone CI brief — competitive landscape report
- Acamprosate or Naltrexone updates RSS · CI watch RSS
- Central Institute of Mental Health, Mannheim portfolio CI